A look at a bispecific antibody program advancing toward clinical testing for advanced solid tumors, emphasizing preclinical efficacy and platform versatility.
Key Takeaways
- HBM7004 is a B7H4xCD3 bispecific that activates T cells within tumors specifically
- In multiple animal models, HBM7004 demonstrated strong anti-tumor efficacy and remarkable in vivo stability
- HBM7004 showed synergistic effects with a B7H4x4-1BB bispecific, suggesting a favorable therapeutic window